Results 21 to 30 of about 9,834 (223)

Intravitreal Dexamethasone Implantation in Intravitreal Bevacizumab Treatment-resistant Pseudophakic Cystoid Macular Edema. [PDF]

Korean J Ophthalmol, 2019
Purpose To evaluate the changes in visual acuity (VA) and central macular thickness (CMT) after intravitreal dexamethasone (IVD) implantation in intravitreal bevacizumab (IVB) treatment-resistant cases with pseudophakic cystoid macular edema (PCME ...
Altintas AGK, Ilhan C.
europepmc   +2 more sources

Topical three-drug combination in the management of pseudophakic cystoid macular edema

Journal of Clinical Ophthalmology and Research
The purpose was to report the outcome after usage of three topical eyedrops combination, consisting of one steroid, one carbonic anhydrase inhibitor (CAI), and one non-steroidal anti-inflammatory drug (NSAID) in the treatment of pseudophakic cystoid ...
Siddharth Sane, Prabhushanker Mahalingam, Geetha Ganesan   +2 more
doaj   +2 more sources

Vitreous hyper-reflective dots in pseudophakic cystoid macular edema assessed with optical coherence tomography. [PDF]

PLoS ONE, 2017
This study compares the presence of vitreous hyper-reflective dots (VHDs) detected with optical coherence tomography (OCT) between eyes with pseudophakic cystoid macular edema (CME) and those with no CME after cataract surgery.
Wilfried Glatz, Gernot Steinwender, Lisa Tarmann, Eva Maria Malle, Marlene Schörkhuber, Werner Wackernagel, Goran Petrovski, Andreas Wedrich, Domagoj Ivastinovic   +8 more
doaj   +2 more sources

Pseudophakic cystoid macular edema prevention and risk factors; prospective study with adjunctive once daily topical nepafenac 0.3% versus placebo. [PDF]

BMC Ophthalmol, 2017
BackgroundDefine the effectiveness of a topical non-steroidal anti-inflammatory drug (NSAID) added to topical steroid use after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular edema (PCME) using a prospective ...
McCafferty S, Harris A, Kew C, Kassm T, Lane L, Levine J, Raven M.   +6 more
europepmc   +2 more sources

Evaluation of Predictive Factors for Successful Intravitreal Dexamethasone in Pseudophakic Cystoid Macular Edema [PDF]

Journal of Ophthalmology, 2017
Purpose. To determine the efficacy, safety, and predictive outcome factors for intravitreal dexamethasone implant (DEX) in pseudophakic cystoid macular edema (PCME). Methods. Retrospective, interventional, controlled study.
Vinodh Kakkassery, Tim Schultz, Marc Ilan Wunderlich, Marc Schargus, H. Burkhard Dick, Jörg Rehrmann   +5 more
doaj   +2 more sources

Factors associated with outcomes of intravitreal triamcinolone injection among pseudophakic cystoid macular edema patients at KCMC from 2017 to 2023 [PDF]

International Journal of Health Sciences
Background: Pseudophakic cystoid macular oedema (PCME), also known as Irvine–Gass syndrome, is a postoperative complication of cataract surgery characterized by cystic retinal changes and potential vision loss. Intravitreal triamcinolone acetonide (IVTA)
Kimario, Agathon, Kiwaley, Jackline, Makupa, Andrew, Makupa, William, Rwiza, Justus   +4 more
core   +3 more sources

Factors predicting response of pseudophakic cystoid macular edema to topical steroids and nepafenac

Indian Journal of Ophthalmology, 2018
Purpose: The purpose of this study is to determine factors predicting resolution of acute pseudophakic cystoid macular edema (PCME) after 6 weeks of topical prednisolone and nepafenac application.
Sabyasachi Sengupta, Dhaivat Vasavada, Utsab Pan, Manavi Sindal   +3 more
doaj   +2 more sources

Efficacy of intravitreal dexamethasone implant for prostaglandin-induced refractory pseudophakic cystoid macular edema: case report and review of the literature

Clinical Ophthalmology, 2014
Matteo Sacchi, Edoardo Villani, Francesca Gilardoni, Paolo Nucci University Eye Clinic, San Giuseppe Hospital, University of Milan, Milan, Italy Background: Macular edema is a known complication even after uneventful cataract surgery.
Sacchi M, Villani E, Gilardoni F, Nucci P   +3 more
doaj   +2 more sources

Efficacy of faricimab for recalcitrant multifactorial cystoid macular edema [PDF]

American Journal of Ophthalmology Case Reports
Purpose: More information is emerging on faricimab-svoa (faricimab) used for etiologies beyond wet age-related macular degeneration (AMD) and diabetic macular edema (DME), including ongoing trials for use in macular edema following retinal vein occlusion
Justin Hanson, Marcus Yamamoto, Edmund Tsui, Irena Tsui   +3 more
doaj   +2 more sources

Longstanding refractory pseudophakic cystoid macular edema resolved using intravitreal 0.7 mg dexamethasone implants

Clinical Ophthalmology, 2013
Troels Brynskov,1,2 Caroline Schmidt Laugesen,1 Jakob Halborg,1 Henrik Kemp,1 Torben Lykke Sørensen1,21Department of Ophthalmology, Copenhagen University Hospital Roskilde, Roskilde, Denmark; 2Faculty of Health Sciences, University of Copenhagen ...
Brynskov T, Laugesen CS, Halborg J, Kemp H, Sørensen TL   +4 more
doaj   +2 more sources